Macconi D, Noris M, Benfenati E, Quaglia R, Pagliarino G, Remuzzi G
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Life Sci. 1991;48(15):1429-37. doi: 10.1016/0024-3205(91)90179-f.
Platelet activating factor (PAF) is present in urine from humans and experimental animals in normal conditions. Very little is known about changes in PAF urinary excretion under pathologic conditions and no data are available about the origin of PAF in the urine. In the present study we explored the possibility that immunologic renal disease is associated with an increase in PAF urinary excretion using gas chromatography-mass spectrometry technique. To clarify the renal or extrarenal origin of urinary PAF we evaluated whether exogenously administered PAF (1-[1', 2'-3H]alkyl) is filtered through the glomerulus and excreted in the urine. The results show that: 1) urine from mice with lupus nephritis in the early phase of the disease contained amounts of PAF comparable to those excreted in normal mouse urine, 2) PAF levels increased when animals started to develop high grade proteinuria, 3) after intravenous injection of [3H] PAF in nephritic mice, a negligible amount of [3H] ether lipid, corresponding to [3H]1-alkyl -2-acyl-3-phosphocholine (alkyl-2-acyl-GPC), was recovered from the 24 h urine extract.
血小板活化因子(PAF)在正常情况下存在于人类和实验动物的尿液中。关于病理条件下PAF尿排泄的变化知之甚少,且尚无关于尿液中PAF来源的数据。在本研究中,我们使用气相色谱 - 质谱技术探讨了免疫性肾病与PAF尿排泄增加相关的可能性。为了阐明尿中PAF的肾脏或肾外来源,我们评估了外源性给予的PAF(1 - [1', 2'-3H]烷基)是否通过肾小球滤过并随尿液排出。结果表明:1)狼疮性肾炎小鼠疾病早期的尿液中PAF含量与正常小鼠尿液中排出的量相当;2)当动物开始出现重度蛋白尿时,PAF水平升高;3)在肾病小鼠静脉注射[3H]PAF后,从24小时尿液提取物中回收的与[3H]1 - 烷基 - 2 - 酰基 - 3 - 磷酸胆碱(烷基 - 2 - 酰基 - GPC)相对应的[3H]醚脂数量可忽略不计。